Glutamate is the most abundant excitatory neurotransmitter, present at up to 80-90% of cortical synapses, and participating in many physiologic and pathologic processes ranging from learning and memory to stroke. The tripeptide, glutathione, is one third glutamate and present at up to 10 millimolar intracellular concentrations in brain, contributing to anti-oxidant and anti-inflammatory defense. Because of the substantial amounts of brain glutathione and its rapid turnover, we hypothesized that glutathione is a relevant reservoir of glutamate, and could influence synaptic excitability. We find that diminishing the liberation of glutamate by the glutathione cycle produces decreases in cytosolic glutamate, decreased frequency of miniature excitatory post synaptic potentials (mEPSC), and diminished depolarizationassociated calcium flux. In contrast, pharmacologically decreasing the biosynthesis of glutathione leads to increases in cytosolic glutamate, increased frequency of mEPSC, and increased depolarization-associated calcium release. The glutathione cycle can compensate for decreased excitatory neurotransmission when the glutamate-glutamine shuttle is inhibited. Glutathione may be a physiologic reservoir of glutamate neurotransmitter that bridges anti-inflammatory pathways and glutamatergic functioning.
INTRODUCTION
Glutamate is the most abundant excitatory transmitter in the central nervous system, utilized at 50-70% of cortical synapses. 1, 2 Glutamate participates in diverse physiological processes, such as developmental plasticity and long-term potentiation as well as brain diseases: epilepsy, stroke, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease and schizophrenia. 3 Glutathione is a tripeptide of glutamate, cysteine and glycine, occurring in neurons at concentrations of 2-10 mM; it is the most abundant low molecular weight thiol of bacteria, plant and animal cells. [4] [5] [6] As such, it regulates critical cellular processes such as metabolism of estrogens, prostaglandins, leukotrienes and xenobiotic drugs. Glutathione is well known as an anti-oxidant agent, providing a major line of defense against oxidative and other forms of stress, largely as a cofactor for the glutathione peroxidase and S-transferase Dissociated cortical neuron cultures from Sprague-Dawley rats were prepared as described previously. 17 Primary cortical neurons were maintained in Neurobasal medium® (Life Technologies Corporation) supplemented with 1x B-27 (life technology). Cells were maintained at 37 °C in 5% CO2/95% atmosphere and medium replaced every 3 days. For glutathione and glutamate quantification, cell viability analysis and oxidative stress assay, cells were sub-cultured in 12-well plates at a density of 4.2 x 105 cells/well. For electrophysiological recording, cells were seeded onto 12 mm diameter poly-D-lysine coated glass coverslips at a density of in 24-well plates and grown for 48 hours before experiments.
The media was then replaced with fresh media and treated with 25 
Measurement of glutathione
Total and oxidized glutathione was determined by the Tieze method with minor modifications. 18 Cells were washed in PBS, scraped and suspended in phosphate buffer then sonicated. A portion of lysate was suspended in 0.1% N-lauroylsarcosine and used for analysis of protein content by Bradford assay. 19 The remaining solution was centrifuged 15 minutes at 20,000g and the soluble fraction was used for detection of glutathione content.
Proteins in the remaining fraction were precipitated with 50 mg/mL metaphosphoric acid, removed by centrifugation, and supernatants neutralized with 200 mM triethanolamine. For oxidized glutathione measurement, an aliquot of the supernatant was incubated 60 minutes at room temperature with 10 mM 2-vinylpyridine (2-VP) to scavenge reduced glutathione.
The rate of increase in absorbance at 415 nm, which measures the reduction of 5-5'dithiobis(2-nitrobenzoic acid) by glutathione, reflects the total glutathione content (or oxidized glutathione when 2-VP is added). The concentration of total and oxidized glutathione content in cells was calculated by a calibration curve with standards.
Measurement of glutamate
Cells were collected in phosphate buffer (100 mM sodium phosphate, 1 mM ethylenediaminetetraacetate, pH 7.5) and sonicated and lysates centrifuged to remove insoluble debris. Determination of glutamate was performed by Kusakabe's method. 20 After incubating at 22 °C for 30 minutes, the mixture was measured at a wavelength of 570 nm with a microplate spectrophotometer. The concentration of L-glutamate was then calculated using a standard calibration curve, normalized to protein sample concentrations, and levels expressed as percentage relative to controls.
Calcium imaging
2 days after transfection of pCMV-GCaMP3, cortical neurons were treated with artificial cerebrospinal fluid (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM KCl, 2 mM MgCl2, 0.1 mM CaCl2, 5mM glucose) containing 0.5 μM TTX (Tocris) for 30 min at 37 °C. 100 mM potassium chloride in aCSF was then applied to the calcium concentration was measured by previous methods. [21] [22] [23] [24] Time-lapse fluorescent images were recorded through 20x objective lens every 90 milliseconds by using a fluorescence microscope (Olympus IX81). The series of fluorescence images were collected by line-scan across the apical dendrite at 10-μm distance from cell bodies and analyzed by Slidebook software (Intelligent Imaging Innovations). Basal pixel fluorescence intensity was defined as the average of the last five frames before treatment of 100 mM potassium chloride (F0) and raw pixel fluorescence values in each frame (F) were measured. ΔF/F represents the value of (F -F0)/F. Recordings were made at room temperature in artificial cerebrospinal fluid (aCSF) (pH 7.3, osmolarity 305 +/-5 mOsm/kg) perfused at 2 mL/min containing 150 mM NaCl, 10 mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid, 10 mM glucose, 3 mM potassium chloride, 2 mM calcium chloride, and 1.3 mM magnesium chloride. Putative neurons were identified under visual guidance with infrared differential interference contrast optics (Olympus BX-61-WI) with a 40x water-immersion objective. The image was captured with an infraredsensitive EMCCD camera (IXON DU885K) and displayed on a monitor. In addition, the image was sent to a computer with a serial connector and captured (Metamorph Advanced).
mEPSC recordings
Whole-cell current clamp recordings were made with a headstage (CV-7B) connected to a computer-controlled amplifier (MultiClamp 700B, Axon Instruments), digitized through a Digidata 1440A Analog/digital converter and acquired at a sampling rate of 10 kHz. All current steps to set membrane potential and elicit action potentials were delivered through the recording pipette and controlled by Clampex 10 (Axon). Electrode potentials were adjusted to zero before recording. mEPSCs were recorded in the presence of tetrodotoxin (1 μM, Tocris, Ellisville, MO, USA or Alomone, Jerusalem, Israel) and picrotoxin (0.1mM, Sigma-Aldrich, St. Louis, MO, USA). All voltage clamp recordings were performed at a holding potential of -70mV. mEPSC events were detected using the software MiniAnalysis (Synaptosoft, Decatur, GA, USA) with a 5 pA amplitude threshold and all mEPSCs were verified visually. Data for analysis was excluded if access resistance is more than 50 Mohm or membrane resistance is less than 100 Mohm. Cumulative probability histograms were tested by Kolmogorov-Smirnov Test for each recording from at least 50 events. Mean values for mEPSC frequency and amplitude between groups were analyzed by Tukey-Kramer HSD test. All results are shown as mean +/-S.E.M.
Statistical analysis
All data were expressed as the mean+/-S.E. Statistical differences in glutathione, glutamate measurement and miniature EPSC analysis were done by Tukey-Kramer HSD test, except where noted. Statistical differences between two groups for behavioral tests were determined with Student's t-test. Statistical differences among three groups or more were determined using a one-way analysis of variance (ANOVA), two-way ANOVA, and an ANOVA with repeated measures, followed by Bonferroni's multiple comparison test; p<0.05 was regarded as statistically significant.
RESULTS
To test the hypothesis that glutathione is a significant reservoir for glutamate, we treated neuronal cells with molecular inhibitors targeting enzymes of the glutathione metabolic cycle: As we had previously demonstrated in cell lines, 16 total glutamate levels declined in primary cortical neurons treated with acivicin ( Supplementary Figure 2a -b). To confirm the specificity of this effect, shRNA targeting of GGT also decreased glutamate levels ( Supplementary   Figure 2c ). Additionally, we find that the decrease in glutamate brought by acivicin could be rescued by administration of pyroglutamate [5-oxoproline], a downstream metabolite in the glutathione pathway that is a precursor of glutamate ( Supplementary Figure 1 ). Pyroglutamate selectively repleted glutamate, but not glutathione ( Supplementary Figure 2a To determine if glutamate availability from the glutathione cycle could shape excitatory transmission, we measured the frequency of miniature excitatory postsynaptic currents (mEPSCs), a reflection of presynaptic drive. Acivicin treatment (24 h) significantly decreased mEPSC frequency (Figure 1a-d) . To demonstrate specificity of the effect, we sought to rescue the decreased mEPSC frequency by pretreating with pyroglutamate (PGA), the precursor of glutamate that is synthesized downstream of GGT, which is blocked by acivicin ( Figure 1a ). Pyroglutamate rescued the effect on mEPSC frequency (Figure 1b-d ).
As we previously demonstrated, acivicin treatment at these concentrations did not elicit oxidative stress or affect cell viability. 16 Glutamate cysteine ligase (GCL) is the rate limiting step for glutathione synthesis, and utilizes glutamate as a substrate. Inhibition of GCL with buthionine sulfoximine (BSO) increased neuronal glutamate ( Supplementary Figure 4a) , consistent with our prior findings in cell lines. 16 BSO treatment depleted glutathione rapidly, reflecting its short half-life (1-4 h) as a substrate of multiple enzymes ( Supplementary Figure 4b ). This was confirmed by shRNA to GCLC, the target of BSO, which increased glutamate levels ( Supplementary   Figure 4c ). To further test the role of GCL in modulating glutathione and glutamate, we utilized sulforaphane, which increases GCL expression through activation of the nrf2 pathway. 27 While BSO inhibition of GCL decreased glutathione and increased glutamate, sulforaphane induced GCL, and decreased glutamate while increasing glutathione ( Supplementary Figure 4d-f ). We previously demonstrated that these doses and durations of treatment do not alter cortical neuron viability or increase oxidative stress. 16 BSO was utilized to test whether increasing the liberation of glutamate from the glutathione cycle could shape excitatory transmission. The BSO induced increased in glutamate was accompanied by an increase in mEPSC frequency (Figure 2b-d) .
The glutamate-glutamine shuttle ( Supplementary Figure 4 ) between neurons and glia contributes 50-60% of glutamate neurotransmitter, 12, 13, 28 with intracellular glycolytic products contributing to the remainder. In the shuttle, glutamate is converted to glutamine in astrocytes, and then exported to neuronal system A transporters, where it is converted to glutamate intracellularly by phosphate activated glutaminase. 29 However, glutaminase knockout mice 30 or blockade of system A transporters with methylaminoisobutyric acid (MeAIB) 15 fail to block excitatory neurotransmission. We explored whether the glutathione cycle can complement the actions of the glutamate-glutamine shuttle by blocking import of glutamine by the system A transporter, 15 which imports glutamine into neurons, after which it is converted to glutamate ( Figure 3a ).
As expected, MeAiB decreased mEPSC frequency (Figure 3b-d) . Acivicin, which diminishes the availability of glutathione-derived glutamate, decreased average mEPSC frequency significantly, though not to the same extent as MeAIB (Figure 3d ). mEPSC frequency declined even further when acivicin and MeAIB were co-administered, consistent with glutamate derived from the glutathione cycle having capacity to shape excitatory neurotransmission when glutamine supply is restricted (Figure 3c-d) .
We next examined whether glutamate from the glutathione cycle could rescue mEPSC when glutamine supply was restricted (Figure 4a ). BSO, which augments glutamate levels, also increased mEPSC frequency (Figure 4b-d ), while glutamine restriction by MeAIB decreased mEPSC frequency. However, administration of BSO could rescue the decreased mEPSC frequency brought by MeAIB (Fig 4d, green line) , consistent with the glutathione cycle being able to compensate for decreased availability of glutamine, an established source of glutamate neurotransmitter.
DISCUSSION
We previously reported that the glutathione cycle may serve as a reservoir of total neuronal glutamate. 16 Treatments that decrease the liberation of glutamate from the glutathione cycle lead to decreased intracellular glutamate, whereas decreasing utilization of glutamate for glutathione synthesis increases it. 16 We now report that shunting of glutamate derived from glutathione can shape excitatory neurotransmission. Inhibiting GCL, which utilizes glutamate to synthesize glutathione, leads to increased glutamate and mEPSC frequency.
Decreasing the release of glutamate from the glutathione cycle by blocking GGT leads to diminished mEPSC. We have previously demonstrated that these fluxes of cytosolic glutamate can occur without detectable increases in oxidative stress or altered cell viability. 16 Thus the glutathione pathway is poised to contribute glutamate without impacting neuronal viability unless there are massive, sustained deficits. 16, 31 The glutathione pathway may also supply glutamate when glia derived glutamine is blocked by MeAIB, which inhibits system A transporters. While glia-derived glutamine provides 50-60% of glutamate neurotransmitter, when the pathway is blocked with MeAIB excitatory transmission abruptly decreases but rapidly recovers, consistent with endogenous neuronal sources of glutamate neurotransmitter. 15 We suggest glutathione is one such endogenous source, as further impairing glutamate liberation from the cycle diminishes synaptic activity induced by MeAIB, while increasing glutamate availability can rescues the impairment by MeAIB. A reservoir capacity of glutathione may be utile during periods of sustained synaptic activity.
Alterations in neuronal glutamate levels, such as by fluxes to and from a glutathione reservoir, might have an impact upon glutamate neurotransmitter. Vesicular glutamate transporters have a much lower affinity for glutamate 0.5-3.5 mM than plasma membrane transporters GLT1/EAAT2, whose Km is 4-40 uM 32, 33 . Furthermore, as glutamate neurotransmitter typically does not saturate postsynaptic receptors, modest impacts upon release frequency may influence synaptic strength [34] [35] [36] [37] . Our findings also affirm prior reports that increasing intracellular glutamate concentration in presynaptic terminals leads to greater excitatory post synaptic currents (EPSC) 36, 37 . In our specific approach, we suggest that the glutathione cycle may be one such source of this glutamate. This may provide some mechanistic implications to interpret magnetic resonance spectroscopy techniques in human subjects, in which total regional brain glutamate may be determined, though not provide details on excitatory neurotransmission 38, 39 . "Phasic" axons that fatigue in their glutamate neurotransmitter release have lower glutamate levels than "tonic" glutamate axons with greater glutamate levels 40 . Glutamine levels are similar in both, suggesting that significant reservoirs of glutamate exist in neurons independent of glutamine. Localized glutathione synthesis would be expected to have an even more pronounced effect, and it has been suggested that non-soma areas contain more glutathione 41 .
These findings may be relevant to human disease. Glutamatergic dysfunction has been implicated in schizophrenia by multiple lines of evidence. [42] [43] [44] [45] [46] We suggest that two drugs available for human use, sulforaphane, which increases glutathione, and pyroglutamate, which is converted to glutamate in the glutathione cycle, may be therapeutically beneficial. Sulforaphane 56 is a potent inducer of the Nrf2 transcription factor, has excellent blood brain barrier penetration, 57 and might expand the size of the glutathione reservoir by increasing expression of GCL, the rate liming step in glutathione biogenesis. Sulforaphane has also been reported to improve symptoms of autistic spectrum disorder. 58 Pyroglutamate 59 is a glutamate precursor whose CSF concentration is 120 uM, 60 rivaling the extracellular glutamine concentration of 400 uM (basal glutamate is 2-3 uM). Oral administration of pyroglutamate has been found to benefit age-associated memory impairment, 61 alcoholic encephalopathy, 62 and delirium induced by anticholinergic medication. 63 Pyroglutamate may be a promising therapeutic candidate for cognitive dysfunction in schizophrenia and other conditions with glutathione disturbances. BSO which increases efflux of glutamate from the glutathione cycle, increased mEPSC frequency, a reflection of presynaptic drive (see also Supplementary Figure 4) . ‡, p<0.0001 by Steel-Dwass All Pairs test. 
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